Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to “Sell”

Actuate Therapeutics (NASDAQ:ACTU) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Actuate Therapeutics in a report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Actuate Therapeutics Trading Up 7.0%

Shares of NASDAQ ACTU opened at $5.69 on Friday. Actuate Therapeutics has a twelve month low of $5.08 and a twelve month high of $11.99. The company has a market capitalization of $132.24 million, a price-to-earnings ratio of -6.54 and a beta of -0.15. The firm has a 50-day moving average of $6.51 and a two-hundred day moving average of $6.97.

Actuate Therapeutics (NASDAQ:ACTU) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.02.

Insider Activity

In other news, Director Todd S. Thomson sold 280,000 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $5.80, for a total transaction of $1,624,000.00. Following the transaction, the director directly owned 904,795 shares in the company, valued at $5,247,811. The trade was a 23.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 69.34% of the stock is owned by insiders.

Institutional Investors Weigh In On Actuate Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. lifted its position in shares of Actuate Therapeutics by 98.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock worth $151,000 after purchasing an additional 11,105 shares during the last quarter. Gleason Group Inc. bought a new position in Actuate Therapeutics in the 2nd quarter worth approximately $116,000. Geode Capital Management LLC lifted its holdings in shares of Actuate Therapeutics by 252.5% during the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock worth $721,000 after buying an additional 84,561 shares during the last quarter. Sfmg LLC lifted its holdings in shares of Actuate Therapeutics by 32.3% during the second quarter. Sfmg LLC now owns 14,550 shares of the company’s stock worth $89,000 after buying an additional 3,550 shares during the last quarter. Finally, BIOS Capital Management LP boosted its position in shares of Actuate Therapeutics by 0.7% in the second quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company’s stock valued at $60,887,000 after acquiring an additional 71,428 shares during the period.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.